Viking Therapeutics outlines completion of VANQUISH-1 enrollment by year-end while advancing novel VK2735 maintenance dosing study (NASDAQ:VKTX)
Viking Therapeutics(US:VKTX) Seeking Alpha·2025-10-22 23:34根据提供的文档内容，该文档不包含任何与公司或行业相关的实质性信息 因此无法提取和总结关键要点